Recombinant human platelet-derived growth factor (Tasly/Jinsaishi))

重组人血小板源生长因子（天士力/金赛狮）

Report date: 2022/03/25 13:57:21

Base Information

Drug NameRecombinant human platelet-derived growth factor (Tasly/Jinsaishi))
Drug Alias Name重组人血小板源生长因子（rhPDGF-BB）凝胶剂
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionPlatelet-derived growth factor receptor agonists
TargetsPlatelet-derived growth factor receptor
Therapy Area/IndicationsDiabetes MellitusSkin Ulcer
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesBeijing Jinsaishi Biopharmaceutical Technology Development Co LtdTianjin Tasly Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Jinsaishi Biopharmaceutical Technology Development Co LtdTianjin Tasly Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetes MellitusSkin Ulcer
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A